Meeting of the Advisory Committee on Blood and Tissue Safety and Availability
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Issuing agencies
Abstract
The U.S. Department of Health and Human Services is hereby giving notice that the Advisory Committee on Blood and Tissue Safety and Availability (ACBTSA) will hold a virtual meeting. The meeting will be open to the public. The committee will discuss recommendations to improve the supply chain and data infrastructure that supports the blood industry, especially during public health emergencies. To facilitate this discussion, key stakeholders from across the nation and around the world will present on hemovigilance, preparedness, inventory management systems and other relevant issues.
Full Text
<html>
<head>
<title>Federal Register, Volume 86 Issue 143 (Thursday, July 29, 2021)</title>
</head>
<body><pre>
[Federal Register Volume 86, Number 143 (Thursday, July 29, 2021)]
[Notices]
[Page 40861]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2021-16120]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Meeting of the Advisory Committee on Blood and Tissue Safety and
Availability
AGENCY: Office of the Assistant Secretary for Health, Office of the
Secretary, Department of Health and Human Services.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The U.S. Department of Health and Human Services is hereby
giving notice that the Advisory Committee on Blood and Tissue Safety
and Availability (ACBTSA) will hold a virtual meeting. The meeting will
be open to the public. The committee will discuss recommendations to
improve the supply chain and data infrastructure that supports the
blood industry, especially during public health emergencies. To
facilitate this discussion, key stakeholders from across the nation and
around the world will present on hemovigilance, preparedness, inventory
management systems and other relevant issues.
DATES: The meeting will take place virtually on Tuesday, August 17,
2021 from approximately 10:00 a.m.-6:00 p.m. and Wednesday, August 18,
2021 from approximately 10:00 a.m.-6:00 p.m. Eastern Time (ET). Meeting
times are tentative and subject to change. The confirmed times and
agenda items for the meeting will be posted on the ACBTSA web page at
<a href="https://www.hhs.gov/oidp/advisory-committee/blood-tissue-safety-availability/meetings/2021-08-17/index.html">https://www.hhs.gov/oidp/advisory-committee/blood-tissue-safety-availability/meetings/2021-08-17/index.html</a> when this information
becomes available.
FOR FURTHER INFORMATION CONTACT: James Berger, Designated Federal
Officer for the ACBTSA; Office of Infectious Disease and HIV/AIDS
Policy, Office of the Assistant Secretary for Health, Department of
Health and Human Services, Mary E. Switzer Building, 330 C Street SW,
Suite L600, Washington, DC 20024. Email: <a href="/cdn-cgi/l/email-protection#61202223353220210909124f060e17"><span class="__cf_email__" data-cfemail="edacaeafb9beacad85859ec38a829b">[email protected]</span></a>.
SUPPLEMENTARY INFORMATION: ACBTSA is a discretionary Federal advisory
committee. ACBTSA The Committee is governed by the provisions of the
Federal Advisory Committee Act (FACA), Public Law 92-463, as amended (5
U.S.C. App), which sets forth standards for the formation and use of
advisory committees. On the day of the meeting, please go to <a href="https://www.hhs.gov/live/index.html">https://www.hhs.gov/live/index.html</a> to view the meeting. The public will have
an opportunity to present their views to the ACBTSA orally during the
meeting's public comment session or by submitting a written public
comment. Comments should be pertinent to the meeting discussion.
Persons who wish to provide verbal or written public comment should
review instructions at <a href="https://www.hhs.gov/oidp/advisory-committee/blood-tissue-safety-availability/meetings/2021-08-17/index.html">https://www.hhs.gov/oidp/advisory-committee/blood-tissue-safety-availability/meetings/2021-08-17/index.html</a> and
respond by midnight August 9, 2021, ET. Verbal comments will be limited
to three minutes each to accommodate as many speakers as possible.
Written public comments will be accessible to the public on the ACBTSA
web page prior to the meeting.
ACBTSA functions to provide advice to the Secretary through the
Assistant Secretary for Health on a range of policy issues to include:
(1) Identification of public health issues through surveillance of
blood and tissue safety issues with national survey and data tools; (2)
identification of public health issues that affect availability of
blood, blood products, and tissues; (3) broad public health, ethical,
and legal issues related to the safety of blood, blood products, and
tissues; (4) the impact of various economic factors (e.g., product cost
and supply) on safety and availability of blood, blood products, and
tissues; (5) risk communications related to blood transfusion and
tissue transplantation; and (6) identification of infectious disease
transmission issues for blood, organs, blood stem cells and tissues.
The Committee has met regularly since its establishment in 1997.
Dated: July 23, 2021.
James J. Berger,
Designated Federal Officer, Advisory Committee on Blood and Tissue
Safety and Availability, Office of Infectious Disease and HIV/AIDS
Policy.
[FR Doc. 2021-16120 Filed 7-28-21; 8:45 am]
BILLING CODE 4150-28-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.